Banner
Banner
Specialty Chemicals Ineos AG
Bioscreening Company Directory

Ineos AG
Ineos AG Ineos AG
SO43 Lyndhurst, Hampshire United Kingdom
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

INEOS is a global manufacturer of petrochemicals, specialty chemicals and oil products. It comprises 15 businesses each with a major chemical company heritage. Its production network spans 60 manufacturing facilities in 13 countries throughout the world.

INEOS is characterized by the following strengths:

  • High-quality and low-cost production facilities
  • Well-invested plants
  • Large plants that benefit from economies of scale
  • Favourable locations
  • Experienced management
  • Leading market positions
  • Operating diversity - products, customers, geographic regions, applications and end-use markets

Leading market positions allow INEOS to be the supplier of choice for many of the largest customers in our markets. This has translated into strong and long-term relationships with these customers.

The company continues to grow its profitability and cash flows through:

  • Leveraging existing resources to expand sales
  • Achievement of cost savings
  • Extracting the full benefits of a vertically integrated business
The management philosophy at INEOS is to operate a simple and decentralized organizational structure, coupled with programmes intended to incentivize our employees.
WaySearch
  
Powered by Sigsiu.NET RSS Feeds
Microscope Looks Into Cells of Living Fish
Sulfur Finding May Hold Key to Gaia Theory of Earth as Living Organism
Black Holes Turn Up the Heat for the Universe
Tiny Solar-Panel-Like Cells Help Restore Sight to the Blind
Why Inhibiting DNA Damage-Detecting Enzyme Is Effective in Fighting Cancer and Other Diseases
Pufferfish at the 'Beak' of Evolution: Why Humans Don't Continuously Replace Their Teeth
ScienceDaily (May 16, 2012) — Microscopes provide valuable insights in the structure and dynamics of cells, in particular when the latter remain in their natural environment. However, this is very difficult especially for higher organisms. Researchers of Karlsruhe Institute of Technology (KIT), the Max Planck Institute for Polymer Research, Mainz, and the American National Institutes of Health (NIH) have now developed a new method to visualize cell structures of an eighth of a micrometer in size in living fish larvae. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 13, 2012) — Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases. Read the Full Story
ScienceDaily (May 10, 2012) — A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. Read the Full Story
ScienceDaily (May 14, 2012) — Prickly pufferfish could hold the key to why humans do not continually replace their teeth and may lead to advances in dental therapies. Read the Full Story
image Microscope Looks Into Cells of Living Fish
image Sulfur Finding May Hold Key to Gaia Theory of Earth as Living Organism
image Black Holes Turn Up the Heat for the Universe
image Tiny Solar-Panel-Like Cells Help Restore Sight to the Blind
image Why Inhibiting DNA Damage-Detecting Enzyme Is Effective in Fighting Cancer and Other Diseases
image Pufferfish at the 'Beak' of Evolution: Why Humans Don't Continuously Replace Their Teeth

BioScreening News

  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic...
  • Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
    Pfizer’s drug candidate for advanced renal cell carcinoma (RCC), Torisel, failed to meet the primary endpoint of progression-free survival in the Phase III Intorsect study. The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was...
  • Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
    Biologics manufacturer Lonza and ocular gene therapy specialist Avalanche Biotechnologies established a global manufacturing collaboration to aid in the latter’s gene therapy programs. Avalanche’s lead wet age-related macular degeneration (wet-AMD) gene therapy candidate AVA-101 started in early clinical trials at the end of 2011. The partnership will focus on the...
  • IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
    IntelligentMDx received a CE Mark for its qualitative Group B Streptococcus (GBS) in vitro diagnostic, IMDx GBS, for use on the Abbott m2000™ system. The assay is used to screen for Group B Streptococcus infection in at-risk pregnant women and women in labor. The real-time PCR test can be carried...
  • Admescope to Provide PlexPress Multiplex CYP Gene Expression Analysis Technology
    CRO Admescope will offer PlexPress’ TRAC (transcript analysis with the aid of affinity capture) platform for high-throughput gene expression analysis as part of its in vitro drug interaction and preclinical ADME-Tox services. Finland-based Admescope will initially offer Plexpress’ multiplex cytochrome P450 (CYP) assays. The firm says the service will meet...
  • Six Suitors Join Bristol-Myers in Considering a Bid for Amylin
    After turning down an unsolicited bid from Bristol-Myers Squibb (BMS) in February, Amylin Pharmaceuticals is preparing to weigh offers from BMS and up to six other potential suitors. Citing unnamed “people familiar with the matter,” Bloomberg News reported that BMS has joined AstraZeneca, Merck & Co., Pfizer, Roche, Sanofi, and...
  • Accelr8, Denver Health Win $2M to Develop Battlefield Infections Diagnostic
    Accelr8 and Denver Health received notification that the Defence Medical Research and Development Program (DMRPD) has recommended a $2 million award to support a three-year project focused on developing a rapid diagnostic system for wound infections and serious infections secondary to trauma. The project was the sole recipient of funds...
  • Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy
    Gamida Cell raised $10 million through an internal Series E financing round with all its existing major shareholders. The proceeds will be used to support global commercialization of the firm’s Phase III-stage StemEx cord blood stem cell therapy for blood cancers, and continue development of additional pipeline candidates, including clinical...
  • ALS Institute, Neurotune to Evaluate Amyotrophic Lateral Sclerosis Therapeutic Candidate
    The ALS Therapeutic Institute and Neurotune established a collaboration to evaluate one of the latter’s neuromuscular diseases candidates in an ALS disease model. ALS is associated with motor neurons and their axons becoming disconnected from muscle, and Neurotune has identified a class of compounds designed to maintain neuromuscular junction strength...
  • KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
    CHDI Foundation and KineMed established a collaboration to exploit the latter’s tandem mass spectrometry-based proteomics platform to analyze the in vivo dynamics of mutant huntingtin protein as a means of assessing Huntington disease progression and measuring the efficacy of therapeutic candidates. The aim is to generate data that will both...

Life Science Events

April 2012 May 2012 June 2012
Su Mo Tu We Th Fr Sa
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
Recent events
View full calendar
1 DOW 12,554.92
-43.63 (-0.35%)    
2 S&P 1,319.66
-5.14 (-0.39%)    
3 NASDAQ 2,852.45
-21.59 (-0.75%)